Table 4 Univariate and multivariate Cox regression analysis for PFS and OS in advanced stage epithelial ovarian patients

Age

 ≤ 53

Ref

Ref

Ref

Ref

 > 53

0.88 (0.73–1.06)

0.181

0.91 (0.75–1.11)

0.366

1.04 (0.83–1.29)

0.758

1.09 (0.86–1.39)

0.475

PNI

 Low

Ref

Ref

Ref

Ref

 High

0.71 (0.58–0.87)

 < 0.001

0.87 (0.70–1.07)

0.185

0.62 (0.50–0.78)

 < 0.001

0.77 (0.60–0.99)

0.043

SII

 Low

Ref

Ref

Ref

Ref

 High

1.56 (1.27–1.90)

 < 0.001

1.16 (0.93–1.43)

0.188

1.66 (1.29–2.15)

 < 0.001

1.34 (1.01–1.78)

0.041

Stage

 IIB

Ref

Ref

Ref

Ref

 III

3.40 (2.26–5.10)

 < 0.001

3.02 (1.98–4.60)

 < 0.001

3.38 (2.01–5.69)

 < 0.001

3.17 (1.85–5.44)

 < 0.001

 IV

3.99 (2.51–6.36)

 < 0.001

3.08 (1.90–4.99)

 < 0.001

4.49 (2.52–8.01)

 < 0.001

3.78 (2.09–6.86)

 < 0.001

Histology

 HGSC

Ref

Ref

Ref

Ref

 Others

1.26 (1.01–1.58)

0.040

1.72 (1.37–2.17)

 < 0.001

1.46 (1.14–1.88)

0.003

2.03 (1.56–2.64)

 < 0.001

Comorbidities

 No

Ref

Ref

Ref

Ref

 Yes

0.86 (0.66–1.12)

0.255

0.98 (0.74–1.29)

0.862

1.10 (0.82–1.47)

0.538

1.31 (0.96–1.79)

0.090

Family history of cancer

 No

Ref

Ref

Ref

Ref

 Yes

0.89 (0.68–1.16)

0.400

0.84 (0.64–1.10)

0.198

0.86 (0.62–1.18)

0.339

0.77 (0.56–1.06)

0.113

Lymphadenectomy

 No

Ref

Ref

Ref

Ref

 Yes

0.58 (0.48–0.71)

 < 0.001

0.87 (0.70–1.08)

0.214

0.53 (0.42–0.67)

 < 0.001

0.82 (0.64–1.06)

0.134

Residual disease

 R0

Ref

Ref

Ref

Ref

 R1

1.84 (1.44–2.34)

 < 0.001

1.69 (1.32–2.16)

 < 0.001

2.15 (1.60–2.89)

 < 0.001

1.98 (1.46–2.67)

 < 0.001

 R2

3.22 (2.50–4.13)

 < 0.001

2.62 (2.00–3.44)

 < 0.001

3.48 (2.56–4.72)

 < 0.001

2.85 (2.05–3.94)

 < 0.001